These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 8297815)
21. In vivo antitumor activity of a monoclonal antibody-Vinca alkaloid immunoconjugate directed against a solid tumor membrane antigen characterized by heterogeneous expression and noninternalization of antibody-antigen complexes. Starling JJ; Maciak RS; Law KL; Hinson NA; Briggs SL; Laguzza BC; Johnson DA Cancer Res; 1991 Jun; 51(11):2965-72. PubMed ID: 2032233 [TBL] [Abstract][Full Text] [Related]
22. Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents. Bodey B; Bodey B; Siegel SE; Kaiser HE Curr Pharm Des; 2000 Feb; 6(3):261-76. PubMed ID: 10637379 [TBL] [Abstract][Full Text] [Related]
23. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells. Nam SM; Kim HS; Ahn WS; Park YS Oncol Res; 1999; 11(1):9-16. PubMed ID: 10451027 [TBL] [Abstract][Full Text] [Related]
25. Progression and treatment of HER2-positive breast cancer. Davoli A; Hocevar BA; Brown TL Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739 [TBL] [Abstract][Full Text] [Related]
26. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Lorimer IA; Wikstrand CJ; Batra SK; Bigner DD; Pastan I Clin Cancer Res; 1995 Aug; 1(8):859-64. PubMed ID: 9816055 [TBL] [Abstract][Full Text] [Related]
27. [Targeting therapy directed against growth factor receptor]. Ueda M; Abe O; Shimizu N Tanpakushitsu Kakusan Koso; 1991 May; 36(7):1436-42. PubMed ID: 1871365 [No Abstract] [Full Text] [Related]
28. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody. Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826 [TBL] [Abstract][Full Text] [Related]
29. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704 [TBL] [Abstract][Full Text] [Related]
30. 13. New biological therapies for breast cancer. Plunkett TA; Miles DW Int J Clin Pract; 2002 May; 56(4):261-6. PubMed ID: 12074208 [TBL] [Abstract][Full Text] [Related]
31. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies. Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879 [TBL] [Abstract][Full Text] [Related]
33. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors. Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356 [TBL] [Abstract][Full Text] [Related]
34. TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models. Verma B; Neethling FA; Caseltine S; Fabrizio G; Largo S; Duty JA; Tabaczewski P; Weidanz JA J Immunol; 2010 Feb; 184(4):2156-65. PubMed ID: 20065111 [TBL] [Abstract][Full Text] [Related]
35. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673 [TBL] [Abstract][Full Text] [Related]
36. [The effect of antibody against vascular endothelial growth factor on tumor growth]. Wang G; Wang N; Liu T Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):163-6. PubMed ID: 10920886 [TBL] [Abstract][Full Text] [Related]
37. Enhanced antitumour effects using a combination of two antibodies conjugated to different drugs. Rowland AJ; McKenzie IF; Pietersz GA J Drug Target; 1994; 2(2):113-21. PubMed ID: 8069589 [TBL] [Abstract][Full Text] [Related]
38. [Antitumor effect of the immunoconjugate composed of antibiotic C1027 and Fab fragment from a monoclonal antibody directed against human hepatoma]. Li JZ; Jiang M; Xue YC; Zhen YS Yao Xue Xue Bao; 1993; 28(4):260-5. PubMed ID: 8213168 [TBL] [Abstract][Full Text] [Related]
39. Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients. Durrant LG; Byers VS; Scannon PJ; Rodvien R; Grant K; Robins RA; Marksman RA; Baldwin RW Clin Exp Immunol; 1989 Feb; 75(2):258-64. PubMed ID: 2784738 [TBL] [Abstract][Full Text] [Related]